Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

Summary

Targeting the PD-L1 pathway with atezolizumab has demonstrated objective responses across a broad range of malignancies including head and neck squamous cell carcinoma (SCCHN). MO39839 is a window of opportunity study investigating the feasibility, safety and postoperative complication rates of preoperative short time immunotherapy with atezolizumab in patients with local SCCHN. In the scope of MO39839 a comprehensive translational research program will be conducted to assess the potential effect of atezolizumab on dynamics in tumor immunity, and to identify and validate potential predictive and prognostic biomarkers.

Timeline

Start

2021-10-06

Primary completion

2024-03-14

Completion

2024-03-14

Drugs

Indications